Andrew Spaventa - 12 Feb 2025 Form 4 Insider Report for Singular Genomics Systems, Inc.

Signature
/s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
12 Feb 2025
Net transactions value
-$15,912
Form type
4
Filing time
14 Feb 2025, 17:00:10 UTC
Previous filing
17 Dec 2024
Next filing
25 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMIC Common Stock Options Exercise +1,907 +587% 2,232 12 Feb 2025 Direct F1
transaction OMIC Common Stock Sale $15,912 -800 -36% $19.89 1,432 14 Feb 2025 Direct F2, F3
transaction OMIC Common Stock Gift $0 -1,107 -77% $0.000000 325 14 Feb 2025 Direct F4
transaction OMIC Common Stock Gift $0 +1,107 +0.78% $0.000000 142,900 14 Feb 2025 By The Andrew K. Spaventa Living Trust dated April 9, 2014 F4
holding OMIC Common Stock 85 12 Feb 2025 By Axon Holdings, LLC F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OMIC Restricted Stock Units Options Exercise $0 -1,907 -7.7% $0.000000 22,873 12 Feb 2025 Common Stock 1,907 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.
F3 Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.88 to $19.91, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
F5 The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F6 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7 The RSUs vest in 16 equal quarterly installments over four years measured from February 12, 2024.